Abstract
There is increasing evidence to support the idea that immune modulation is involved in cancer progression. Indeed, the growth in the number of publications describing cancer immunotherapy and how it impacts on cell signaling pathways reinforces this idea. In particular, the forkhead box P3 (Foxp3) transcription factor is an important protagonist in regulatory T cell (Treg) suppression, which has recently been reported to be mediated by the PI3-kinase/AKT/mTOR and TGF-β signaling cascades. This could provide an exciting facet of carcinogenesis, by linking modulation of immuneeffector cells and tumourogenesis of cancer cells. Furthermore, recent findings have indicated a direct role for Foxp3 within tumour cells, and its expression in Tregs has been used as an indicator of poor prognosis in cancer patients. Therapeutic modulation of these systems thus provides an attractive approach to cancer treatment. Additionally, drugcombination strategies utilising agents that target signaling pathways may prove beneficial by simultaneously targeting tumour and immune cells, thereby enhancing native immune response to growing tumours. This article will review the factors involved in Foxp3 expression and highlight the means by which Foxp3-expressing cells could be targeted as a part of cancer immunotherapy.
Keywords: Foxp3, regulatory T cell, cancer, signaling, target, therapy
Current Signal Transduction Therapy
Title: The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Volume: 4 Issue: 2
Author(s): Brendan Meyer, Wai M. Liu, Angus G. Dalgleish and Christine Galustian
Affiliation:
Keywords: Foxp3, regulatory T cell, cancer, signaling, target, therapy
Abstract: There is increasing evidence to support the idea that immune modulation is involved in cancer progression. Indeed, the growth in the number of publications describing cancer immunotherapy and how it impacts on cell signaling pathways reinforces this idea. In particular, the forkhead box P3 (Foxp3) transcription factor is an important protagonist in regulatory T cell (Treg) suppression, which has recently been reported to be mediated by the PI3-kinase/AKT/mTOR and TGF-β signaling cascades. This could provide an exciting facet of carcinogenesis, by linking modulation of immuneeffector cells and tumourogenesis of cancer cells. Furthermore, recent findings have indicated a direct role for Foxp3 within tumour cells, and its expression in Tregs has been used as an indicator of poor prognosis in cancer patients. Therapeutic modulation of these systems thus provides an attractive approach to cancer treatment. Additionally, drugcombination strategies utilising agents that target signaling pathways may prove beneficial by simultaneously targeting tumour and immune cells, thereby enhancing native immune response to growing tumours. This article will review the factors involved in Foxp3 expression and highlight the means by which Foxp3-expressing cells could be targeted as a part of cancer immunotherapy.
Export Options
About this article
Cite this article as:
Meyer Brendan, Liu M. Wai, Dalgleish G. Angus and Galustian Christine, The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy, Current Signal Transduction Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157436209788167475
DOI https://dx.doi.org/10.2174/157436209788167475 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutic Target Hsp90 and Cancer Hallmarks
Current Pharmaceutical Design Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Recent Patents on Anti-Cancer Drug Discovery Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Copper-62 Labeled ReCCMSH Peptide Analogs for Melanoma PET Imaging
Current Radiopharmaceuticals Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry NBN Polymorphysms and Cancer Susceptibility: A Systematic Review
Current Genomics γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design An Insight of Molecular Mechanisms and Patents of Biomarkers of Human Papilloma Virus Associated with Cancer : A Review
Recent Patents on Biomarkers Dietary Prevention of Cancer: Anticancer and Antiangiogenic Properties of Green Tea Polyphenols
Medicinal Chemistry Reviews - Online (Discontinued) Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer
Current Drug Therapy Emerging Therapeutic Agents for Cervical Cancer
Recent Patents on Anti-Cancer Drug Discovery Copper Transport Systems are Involved in Multidrug Resistance and Drug Transport
Current Medicinal Chemistry C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design